D. E. Shaw & Co., Inc. Akebia Therapeutics, Inc. Transaction History

D. E. Shaw & Co., Inc.

$125 Billion
Q2 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 219,089 shares of AKBA stock, worth $679,175. This represents 0.0% of its overall portfolio holdings.

Number of Shares

219,089

Previous 73,161 199.46%

Holding current value

$679,175

Previous $140,000 469.29%

% of portfolio

0.0%

Previous 0.0%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$1.55 - $3.97 $226,188 - $579,334	145,928 Added 199.46%	219,089 $797,000
Q1 2025 May 15, 2025	SELL	$1.69 - $2.84 $16,055 - $26,980	-9,500 Reduced 11.49%	73,161 $140,000
Q4 2024 Feb 14, 2025	SELL	$1.26 - $2.13 $378 - $639	-300 Reduced 0.36%	82,661 $153,000
Q3 2024 Nov 14, 2024	BUY	$0.94 - $1.55 $77,983 - $128,589	82,961 New	82,961 $109,000
Q2 2022 Aug 15, 2022	SELL	$0.32 - $0.67 $7,215 - $15,106	-22,547 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.72 - $2.93 $5,870 - $23,891	8,154 Added 56.65%	22,547 $16,000
Q4 2021 Feb 14, 2022	BUY	$2.26 - $3.34 $32,528 - $48,072	14,393 New	14,393 $33,000
Q1 2021 May 17, 2021	SELL	$2.92 - $5.06 $1.22 Million - $2.11 Million	-416,583 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$2.22 - $3.78 $3.58 Million - $6.1 Million	-1,613,787 Reduced 79.48%	416,583 $1.17 Million
Q3 2020 Nov 16, 2020	SELL	$2.39 - $13.08 $696,534 - $3.81 Million	-291,437 Reduced 12.55%	2,030,370 $5.1 Million
Q2 2020 Aug 14, 2020	BUY	$6.67 - $13.58 $6.74 Million - $13.7 Million	1,009,842 Added 76.97%	2,321,807 $31.5 Million
Q1 2020 May 15, 2020	BUY	$4.1 - $10.24 $2.15 Million - $5.37 Million	524,334 Added 66.57%	1,311,965 $9.95 Million
Q4 2019 Feb 14, 2020	BUY	$3.16 - $6.73 $1.2 Million - $2.55 Million	378,588 Added 92.55%	787,631 $4.98 Million
Q3 2019 Nov 14, 2019	SELL	$3.55 - $5.4 $417,298 - $634,764	-117,549 Reduced 22.32%	409,043 $1.6 Million
Q2 2019 Aug 14, 2019	BUY	$4.1 - $8.05 $716,700 - $1.41 Million	174,805 Added 49.69%	526,592 $2.55 Million
Q1 2019 May 15, 2019	SELL	$5.41 - $8.73 $353,765 - $570,863	-65,391 Reduced 15.67%	351,787 $2.88 Million
Q4 2018 Feb 14, 2019	BUY	$5.39 - $9.15 $1.68 Million - $2.86 Million	312,207 Added 297.42%	417,178 $2.31 Million
Q3 2018 Nov 14, 2018	BUY	$7.44 - $10.65 $188,946 - $270,467	25,396 Added 31.91%	104,971 $927,000
Q2 2018 Aug 14, 2018	BUY	$9.15 - $11.34 $437,928 - $542,743	47,861 Added 150.91%	79,575 $794,000
Q1 2018 May 15, 2018	SELL	$9.53 - $15.68 $187,121 - $307,876	-19,635 Reduced 38.24%	31,714 $302,000
Q4 2017 Feb 14, 2018	SELL	$14.24 - $19.59 $691,893 - $951,838	-48,588 Reduced 48.62%	51,349 $764,000
Q3 2017 Nov 14, 2017	BUY	$13.06 - $19.67 $1.31 Million - $1.97 Million	99,937	99,937 $1.97 Million

Others Institutions Holding AKBA

# of Institutions

173

Shares Held

106M

Call Options Held

134K

Put Options Held

262K

View Full List

About Akebia Therapeutics, Inc.

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $570M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

More about AKBA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account